The content on this site is intended for healthcare professionals only
Geof Saunders speaks to ecancer at the 2019 Biosimilars Educational Advanced Masterclass for Pharmacists (P-BEAM) in Zurich about introducing a biosimilar of trastuzumab into clinical practice.
He speaks about the processes behind the implementation of this biosimilar, which included a variety of staff across different disciplines.
Saunders also reflects on the feedback from this, especially from patients and how these processes could be improved for the future.
ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.
If you would like to learn more about biosimilar medicines, please visit our free e-learning modules here.
Synthetic biology and precision medicine in blood and gynaecological cancers
Adagrasib shows durable clinical benefit in advanced KRAS-mutant NSCLC
OncoAlert Round Up for September 15-21, 2023
OncoAlert Round Up for August 25th - 31st, 2023
TARGeted IORT INTRABEAM is a useful treatment option for early stage breast cancer
TARGIT-E: Intraoperative Radiotherapy (IORT) in elderly patients with small breast cancer
The use of IORT at Universitätsmedizin Mannheim hospital
Tusamitamab ravtansine combined with SoC shows encouraging anti-tumour activity for patients with nonsquamous NSCLC
Initial results from a phase 1 dose escalation trial of E-602 shows efficacy in solid tumours
